5 Best Dividend Stocks To Buy For 2014

Aeropostale (NYSE: ARO  ) is going south of the border.

On Monday, the clothing chain announced it is signing a licensing agreement with local Mexican department store operator Distribuidora Liverpool. Aeropostale will begin opening store-in-store shops within Liverpool department stores this summer. Simultaneously, Aeropostale will begin opening standalone stores, beginning in the Sante Fe Mall in Mexico City this summer.

CEO Thomas P. Johnson explained the move by calling Mexico “a pivotal market,” and praising Liverpool for its “incredible insight and experience into the consumer as the operator of Mexico’s largest and preeminent department store.”

For its part, Liverpool Commercial Director Graciano Guichard Gonzalez said that company is “excited to capitalize on the popularity and recognition of the Aeropostale brand in Mexico.”

Investors were less excited. Aeropostale shares dropped 0.4% in Monday trading, closing at $13.75. 

5 Best Dividend Stocks To Buy For 2014: TotalFinaElf S.A.(TOT)

TOTAL S.A., together with its subsidiaries, operates as an integrated oil and gas company worldwide. The company operates through three segments: Upstream, Downstream, and Chemicals. The Upstream segment engages in the exploration, development, and production of oil and natural gas. It also involves in the transportation, trade, and marketing of natural gas and liquefied natural gas (LNG), as well as in LNG re-gasification and natural gas storage operations. In addition, this segment engages in the shipping and trade of liquefied petroleum gas (LPG); power generation from gas-fired power plants, nuclear, or renewable energies; production, trade, and marketing of coal, as well as in solar power systems and technology operations. As of December 31, 2010, it had combined proved reserves of 10,695 Mboe of oil and gas. The Downstream segment involves in refining, marketing, trading, and shipping crude oil and petroleum products. It also produces a range of specialty products, s uch as lubricants, LPG, jet fuel, special fluids, bitumen, marine fuels, and petrochemical feedstock. This segment holds interests in 24 refineries located in Europe, the United States, the French West Indies, Africa, and China, as well as operates a network of 17,490 service stations. The Chemicals segment produces base chemicals, including petrochemicals and fertilizers, as well as engages in rubber processing, resins, adhesives, and electroplating activities. TOTAL S.A. was founded in 1924 and is based in Paris, France.

Advisors’ Opinion:

  • [By Jayson Derrick]

    Total (NYSE: TOT) is considering a sale of its TotalGAz liquefied petroleum gas marketing unit for approximately $1.04 billion. Shares lost 0.82 percent, closing at $64.39.

  • [By Aaron Levitt]

    Three more rigs will delivered this year and next. Those rigs in operation are contracted out to energy giants Chevron (CVX), Total (TOT) and Petrobras (PBR). And having three of the largest oil majors sending you checks every day has worked in PACD’s favor.

  • [By Jim Jubak]

    Shares of energy companies without any near-term way to take advantage of any stoppage were off, with Chesapeake Energy (CHK) down 1.2% and France’s Total (TOT) off 2.31%.

5 Best Dividend Stocks To Buy For 2014: Laboratory Corporation of America Holdings(LH)

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company in the United States. The company offers a range of testing services used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease, as well as specialty testing services. Its routine tests include blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, HIV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company?s specialty tests and related services comprise viral load measurements, genotyping and phenotyping, and host genetic factors for managing and treating HIV infections; cytogenetic, molecular cytogenetic, biochemical, and molecular genetic tests for diagnostic genetics; oncology tests for diagnosing and monitoring certain cancers and treatments; clinical trials testing for pharmaceutical companies, which conducts clinical research trials on diag nostic assays; forensic identity testing used in criminal proceedings and parentage evaluation services, as well as testing services in reconstruction cases; allergy testing; and occupational testing for the detection of drug and alcohol abuse. Its customers include independent physicians and physician groups, hospitals, managed care organizations, governmental agencies, employers, pharmaceutical companies, and other independent clinical laboratories. The company operates a network of 51 primary laboratories and approximately 1,700 patient service centers. In addition, it delivers a co-branded electronic health records Lite solution for physician practices. The company works with university, hospital, and academic institutions, such as Duke University, The Johns Hopkins University, the University of Minnesota, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlingt o n, North Carolina.

Advisors’ Opinion:

  • [By Monica Wolfe]

    Over the past week Chris Davis (Trades, Portfolio) of Davis Selected Advisers added to his holdings in Laboratory Corporation of America (LH).  The guru upped his stake 21.11% by purchasing 1,666,957 shares of the company’s stock.  He bought these shares at an average price of $91.37 per share, and since then the price per share is up about 1% to $92.57 per share.

  • [By Ben Levisohn]

    Any time a stock falls more than 10% in a single day, you know something has gone wrong. Such is the case with medical-testing provider Laboratory Corporation of America (LH), or LabCorp.

5 Best Dividend Stocks To Buy For 2014: Smith & Nephew SNATS Inc.(SNN)

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the orthopaedics, endoscopy, and advanced wound management sectors worldwide. The company operates in three segments: Orthopaedics, Endoscopy, and Advanced Wound Management. The Orthopaedics segment offers reconstruction implants, including hip, knee, and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. This segment also provides trauma fixation products consisting of internal and external devices, and other products, including shoulder fixation and orthobiological materials used in the stabilization of fractures and deformity correction procedures; and clinical therapies products comprising bone growth stimulation, joint fluid therapies, and outpatient spine products. The Endoscopy segment develops and commercializes minimally invasive surgery techniques, educational programs, and value-added services for sur geons to treat and repair soft tissue and articulating joints. It offers specialized devices and fixation systems to repair damaged tissues; fluid management equipment for surgical access; digital cameras, digital image capture, scopes, light sources, and monitors to assist with visualisation; radiofrequency wands, electromechanical and mechanical blades, and hand instruments for resecting damaged tissues. The Advanced Wound Management segment provides initial wound bed preparation and full wound closure products. This segment?s products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers; and products for the treatment of wounds, including burns and invasive surgery. The company serves medical and surgical service providers. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Top Headline
    Smith & Nephew PLC (NYSE: SNN) announced its plans to buy ArthroCare (NASDAQ: ARTC) for $1.7 billion in cash. Smith & Nephew will pay $48.25 per share in cash to acquire ArthroCare, representing a 6.3% premium to ArthroCare’s closing price on January 31.

  • [By Jake L’Ecuyer]

    Top Headline
    Smith & Nephew PLC (NYSE: SNN) announced its plans to buy ArthroCare (NASDAQ: ARTC) for $1.7 billion in cash. Smith & Nephew will pay $48.25 per share in cash to acquire ArthroCare, representing a 6.3% premium to ArthroCare’s closing price on January 31.

  • [By James Brumley]

    All that being said, while St. Jude Medical might have never been known as a device pioneer, the acquisitions of Nanostim and Endosense have given STJ stock holders some exposure to pacemakers without pesky leads (where the “pulse” is created), and exposure to atrial fibrillation treatment without the use of drugs. This year might mark a serious upgrade for the company’s product lines.

    Medical Devices: Smith & Nephew plc (SNN)

    Priced at a trailing P/E of 24 and a forward-looking P/E of 17, it’s not like you can call Smith & Nephew plc (SNN) a screaming value. It’s a reliable growth machine, however, in terms of earnings as well as revenue.

  • [By Royston Wild]

    LONDON — Shares in Smith & Nephew  (LSE: SN  ) (NYSE: SNN  ) have risen steadily in recent months, and were recently up 11% in the year to date.

5 Best Dividend Stocks To Buy For 2014: Vornado Realty Trust(VNO)

Vornado Realty Trust is a privately owned real estate investment trust. The trust engages in investment, ownership, and management of commercial real estate. It invests in the real estate markets of United States. The trust primarily invests in office, industrial and retail properties. Vornado Realty Trust is based in New York, New York.

Advisors’ Opinion:

  • [By Robert Hsu]

    Name Type of Security  Recommendation  Kinder Morgan Energy Partners L.P. (NYSE: KMP)   MLP August 15, 2013  TeeKay LNG Partners L.P.  (NYSE: TGP)   MLP September 16, 2013  PowerShares S&P 500 BuyWrite Portfol ETF  (NYSE Arca: PBP)  Buy-Write ETF September 30, 2013  Madison Covered Call Equity Strtgy Fd (NYSE: MCN)  Buy-Write ETF September 30, 2013  Nuveen Equity Premium Opportunity Fund (NYSE: JSN)  Buy-Write ETF September 30, 2013  BlackRockEnhanced Dividend Achievers Tr (NYSE: BDJ)  Buy-Write ETF September 30, 2013  Vornado Realty Trust   (NYSE: VNO)  Real Estate
    Investment
    Trust September 26, 2013 

    Robert Hsu is the editor of Permanent Wealth Investor and a former hedge fund portfolio manager at Wall Street powerhouse Goldman Sachs. He retired from Goldman at age 31. He since has come out of retirement to establish and preside over his money management firm, Absolute Return Capital Advisors. His retirement experience has given him his current mission: helping investors like you achieve their goal of comfortable retirement through profitable income strategies.

  • [By Dividend King]

    Earnings per share (TTM) came in at $3.48, compared to -$0.33, $1.46, and $4.17 for competitors General Growth Properties Inc. (GGP), Macerich Co. (MAC) and Vornado Realty Trust (VNO), respectively.

  • [By Robert Hsu]

    And Vornado Realty Trust (NYSE: VNO) is one of these big buyers.

    The Manhattan-based real estate investment trust (REIT) owns more than 28 million square feet of high-end office, retail, and residential space in its home town. (You can tour its New York properties right here.)

  • [By CRWE]

    VORNADO REALTY TRUST (NYSE:VNO) reported that its Board of Trustees has declared a regular quarterly dividend of $0.69 per share payable on August 21, 2012 to common shareholders of record on August 10, 2012.

5 Best Dividend Stocks To Buy For 2014: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women’s health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Advisors’ Opinion:

  • [By Vanina Egea]

    The first on the list is Pfizer Inc. (PFE), in which Blackhill disclosed a $23.6 million stake with over 772,140 shares. Pfizer is a biopharmaceutical company which sells health care products worldwide. It operates in a highly competitive industry with Merck & Co. Inc. (MRK), Novartis AG (NVS) and Sanofi (SNY). It has reported fourth quarter EPS and revenues above the Zacks Consensus Estimate. It has a proven commitment to returning cash to investors, with a current dividend yield of 3% which is considered quite good to protect investors’ purchasing power. The company returned about $15 billion to shareholders (dividends and share buybacks) in 2012.

  • [By Louis Navellier]

    Ligand Pharmacuticals (LGND) is a biotech company that focuses on acquisition and development of royalty revenue generating assets in the United States. Ligand has relationships with most of the leading drug companies including GlaxoSmithKline (GSK), Merck (MRK), Bristol-Myers (BMY), Eli Lilly (LLY) and others.